➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
Dow
Merck
Colorcon

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Aflibercept - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for aflibercept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Southeastern Retina AssociatesPhase 2
University of California, Los AngelesPhase 2
Eye Associates of New MexicoPhase 2

See all aflibercept clinical trials

Recent Litigation for aflibercept

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.2020-06-19
Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.2011-02-17
Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.2010-11-18

See all aflibercept litigation

PTAB Litigation
PetitionerDate
Regeneron Pharmaceuticals, Inc.2020-07-16

See all aflibercept litigation

Company Disclosures: US Patents for aflibercept

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2019-06-08 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-02-26 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-02-26 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-03-29 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for aflibercept

These patents were identified by searching patent claims

Supplementary Protection Certificates for aflibercept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13C/029 Belgium   Start Trial PRODUCT NAME: AFLIBERCEPT; AUTHORISATION NUMBER AND DATE: EU/1/12/197/001 20121126
2013009,C1183353 Lithuania   Start Trial PRODUCT NAME: AFLIBERCEPTUM; REGISTRATION NO/DATE: EU/1/12/797/001, 2012 11 22 EU/1/12/797/002, 2012 11 22 EU/1/12/814 20130201
2013 00020 Denmark   Start Trial
90020-4 Sweden   Start Trial PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/12/797/001 20121122
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Medtronic
Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.